CRNX News and Press, Crinetics Pharmaceuticals Inc. From 05/06/21

Crinetics Pharmaceuticals (CRNX): Q1 GAAP EPS of -$0.69 misses by $0.04.Cash, cash equivalents and investments of $150.7MPress Release For further details see: Crinetics Pharmaceuticals EPS misses by $0.04

Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company foc...

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced tod...

Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...

Crinetics Pharmaceuticals (CRNX) has priced its public offering of ~4.6M common shares at $16.44/share, for expected gross proceeds of ~$75M. Net proceeds will be used to fund the development of paltusotine and other R&D programs, for working capital and general corporate purposes. SVB Le...

The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2020 Earnings Conference Call March 30, 2021, 16:30 ET Company Participants Corey Davis - IR Scott Struthers - Founder, President, CEO & Director Alan Krasner - Chief Medical Officer Marc Wilson - CFO & Secretary Conference Call Participants C...

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively Management hosting webcast and conference call today at 4:30 p.m. ET ...

SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announ...

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today provid...